Compare Incyte Corporation (INCY) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Incyte Corporation trades at $117.91 (market cap $23.11B), while Direxion Daily TSLA Bull 2X Shares trades at $11.32. The key difference: Incyte Corporation is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| INCY | TSLL | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $118.52 | $23.03 |
52-Week Low | $67.38 | $10.29 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
TSLL is trading at $10.72, down 5.84% with a bearish technical outlook. The stock faces selling pressure with moving averages indicating a downtrend and key resistance at $12. Recent news highlights upcoming Tesla earnings as a potential catalyst, though financial ratios remain unavailable for fundamental assessment.
The stock's outlook is cautious due to technical weakness and lack of current financial data. Investment opportunity hinges on Tesla's upcoming earnings report, while risks include sustained bearish momentum and dependency on Tesla's performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
